Product Liability: Discussions With FDA Remain Key In Defeating State Tort Suits
Executive Summary
US Supreme Court says judges, not juries, should decide if FDA would have rejected additional label warning; Merck appears to have the support of three justices who note FDA's position that it decided not to require a change to Fosamax labeling.
You may also be interested in...
Tylenol Label Warning Complaint Dismissed With Judge's Federal Preemption Question Unanswered
Marketers of other drugs available under FDA OTC monograph should note dismissal of complaint against Kenvue didn’t resolve the judge’s questions about whether federal preemption precludes challenges to safety and labeling.
Merck Freed From Fosamax Product Liability Suits Based On US FDA Complete Response Letter
District court dismisses more than 500 cases alleging Merck failed to warn of the risks of its osteoporosis drug, following path set by US Supreme Court in its ruling on the litigation three years ago.
GSK’s Victory In Zofran Product Liability Cases Shows Power Of Communications With US FDA
In granting GlaxoSmithKline’s motion for summary judgment in multidistrict litigation, judge notes FDA rejected requests to change warning label about use in pregnant women multiple times and would not have approved warnings sought by plaintiffs.